Canvaxin, a therapeutic cancer vaccine, may prolong survival of stage IV melanoma after complete resection, according to the results of a prospective phase II trial reported in the Dec. 1 issue of the Journal of Clinical Oncology. A randomized prospective trial is underway at 40 cancer centers in the U.S., Europe, and Australia.
“The curative effect of surgery in certain patients with metastatic melanoma suggests the presence of endogenous antitumor responses,” write Eddy C. Hsueh and colleagues from the John Wayne Cancer Institute, Saint John’s Health Center in Santa Monica, California. “Because melanoma is immunogenic, we investigated whether…Canvaxin (CancerVax Corporation, Carlsbad, California) could enhance antitumor immune responses and thereby prolong survival.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!